WallStreetZenWallStreetZen

NASDAQ: VRPX
Virpax Pharmaceuticals Inc Stock

$0.73+0.01 (+1.39%)
Updated May 24, 2024
VRPX Price
$0.73
Fair Value Price
N/A
Market Cap
$849.14k
52 Week Low
$0.63
52 Week High
$11.77
P/E
-0.05x
P/B
-0.7x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$16.89M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-3.58
Operating Cash Flow
-$16M
Beta
0.44
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

VRPX Overview

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VRPX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VRPX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VRPX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
VRPX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more VRPX due diligence checks available for Premium users.

Be the first to know about important VRPX news, forecast changes, insider trades & much more!

VRPX News

Valuation

VRPX fair value

Fair Value of VRPX stock based on Discounted Cash Flow (DCF)
Price
$0.73
Fair Value
$7.81
Undervalued by
90.65%
VRPX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VRPX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.05x
Industry
15.58x
Market
32.03x

VRPX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-0.7x
Industry
6.08x

VRPX's financial health

Profit margin

Revenue
$0.0
Net Income
-$3.2M
Profit Margin
0%
VRPX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$3.1M
Liabilities
$4.3M
Debt to equity
-3.58
VRPX's short-term liabilities ($4.34M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VRPX's short-term assets ($3.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VRPX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VRPX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$7.7M
Investing
$0.0
Financing
$454.0k
VRPX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

VRPX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
VRPX$849.14k+0.69%-0.05x-0.70x
SPRC$798.55k-2.59%-0.29x0.39x
GRI$1.20M-23.00%0.02x0.43x
DRMA$1.50M-2.82%-0.12x0.39x
ATNF$1.53M-2.41%-0.06x-1.60x

Virpax Pharmaceuticals Stock FAQ

What is Virpax Pharmaceuticals's quote symbol?

(NASDAQ: VRPX) Virpax Pharmaceuticals trades on the NASDAQ under the ticker symbol VRPX. Virpax Pharmaceuticals stock quotes can also be displayed as NASDAQ: VRPX.

If you're new to stock investing, here's how to buy Virpax Pharmaceuticals stock.

What is the 52 week high and low for Virpax Pharmaceuticals (NASDAQ: VRPX)?

(NASDAQ: VRPX) Virpax Pharmaceuticals's 52-week high was $11.77, and its 52-week low was $0.63. It is currently -93.84% from its 52-week high and 14.72% from its 52-week low.

How much is Virpax Pharmaceuticals stock worth today?

(NASDAQ: VRPX) Virpax Pharmaceuticals currently has 1,171,233 outstanding shares. With Virpax Pharmaceuticals stock trading at $0.73 per share, the total value of Virpax Pharmaceuticals stock (market capitalization) is $849.14k.

Virpax Pharmaceuticals stock was originally listed at a price of $65.30 in Feb 17, 2021. If you had invested in Virpax Pharmaceuticals stock at $65.30, your return over the last 3 years would have been -98.89%, for an annualized return of -77.69% (not including any dividends or dividend reinvestments).

How much is Virpax Pharmaceuticals's stock price per share?

(NASDAQ: VRPX) Virpax Pharmaceuticals stock price per share is $0.73 today (as of May 24, 2024).

What is Virpax Pharmaceuticals's Market Cap?

(NASDAQ: VRPX) Virpax Pharmaceuticals's market cap is $849.14k, as of May 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Virpax Pharmaceuticals's market cap is calculated by multiplying VRPX's current stock price of $0.73 by VRPX's total outstanding shares of 1,171,233.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.